BioSpace News Archive

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has successfully completed its dose-ranging toxicology studies in rats and dogs, for its lead drug candidate MB-204.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects (“PCED”), a rare ocular condition characterized by non-healing wounds on the surface of the eye.

Mobius Therapeutics™, LLC, a St. Louis-based perioperative ophthalmic pharmaceutical company, has been issued US Patent #11,540,977, Injection Apparatus and Method of Use.

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Standard Time.

The global 5G in healthcare market size accounted for USD 48.25billion in 2022 and is expected to attain around USD 459.71 billion by 2030 with a noteworthy CAGR of 32.55% from 2022 to 2030.

The global molecular diagnostics market size accounted for USD 14.75 bn in 2022 and is expanding around USD 48.9 billion by 2030 with a registered CAGR 16.16% from 2022 to 2030.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF).